Compare HOVR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | CNTB |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Canada | United States |
| Employees | 58 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.3M | 135.7M |
| IPO Year | N/A | 2020 |
| Metric | HOVR | CNTB |
|---|---|---|
| Price | $2.01 | $2.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.33 | $8.67 |
| AVG Volume (30 Days) | ★ 1.4M | 466.9K |
| Earning Date | 04-14-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.16 | $1.23 |
| 52 Week High | $4.18 | $3.82 |
| Indicator | HOVR | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 50.16 |
| Support Level | $1.72 | $1.99 |
| Resistance Level | $2.01 | $2.64 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 81.32 | 54.02 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.